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Dear Editor,
Multidrug-resistant Acinetobacter baumannii (MDR-Acb) has 
increasingly emerged as a problematic pathogen responsible 
for hospital-acquired infections worldwide. Carbapenems and 
aminoglycosides can produce a synergic effect and thus are 
often used together to threat MDR-Acb infections. Therefore, 
strains bearing resistance to these antimicrobial drugs would 
have a considerable clinical impact.
The aim of this study was to explore the resistance 
mechanisms against carbapenems and aminoglycosides and 
the molecular epidemiology of clinical strains of MDR-Acb 
isolated in the Alexandrovska University Hospital (AUH) in 
Sofia, over a six-year period.
A collection of 70 non-duplicate strains of MDR-Acb 
(resistant to representatives of at least three different 
classes of antimicrobial agents such as antipseudomonal 
penicillins, cephalosporins, carbapenems, aminoglycosides, 
and quinolones) was investigated. The strains were recovered 
between January 2005 and September 2011 from inpatients 
admitted to four intensive care units of the AUH. They were 
obtained from tracheobronchial aspirates (twenty-eight), 
surgical wounds (eleven), drainages (ten), blood (six), urine 
(six), central venous catheters (five) and cerebrospinal fluid 
(four). Bacterial identification was performed using BBL Enteric/
Nonfermenter ID System (Becton Dickinson). 
Antimicrobial susceptibility testing was performed by the 
Etest (LIOFILCHEM) according to the Clinical and Laboratory 
Standards Institute 2010 recommendations. The EUCAST-2010 
MIC breakpoints for Enterobacteriaceae were applied to 
interpret the tigecycline MIC results. Susceptibility rates 
to colistin, tigecycline, trimethoprim/sulfamethoxazole, 
ampicillin/sulbactam, and levofloxacin were as follows: 100%, 
77.1%, 64.3%, 24.3%, and 17.1%, respectively. All isolates were 
non-susceptible to ceftazidime and cefepime (MICs > 8 μg/mL). 
A total of 49 of the studied MDR-Acb isolates (70%) were 
carbapenem non-susceptible (MICs ranged from 8 to > 256 μg/mL). 
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Twenty-three strains (32.9%) isolated between 2010 and 2011 
showed high-level resistance to amikacin, gentamicin, and 
tobramycin (MICs > 256 μg/mL).
Multiplex polymerase chain reaction (PCR) for genes 
encoding prevalent OXA carbapenemases in Acinetobacter 
spp.1 detected blaOXA-23-like in all carbapenem non-susceptible 
MDR-Acb, which were confirmed by sequencing. The insertion 
sequence ISAba1 was positively identified by ISAba1/OXA-23 
PCR and was located upstream of blaOXA-23 based on sequence 
analysis. The comparative temporary prevalence of OXA-23 
producers revealed a significantly higher prevalence (p < 0.001, 
Student’s t-test) among the investigated MDR-AcbB isolated 
during 2009-2011 than among those isolated during 2005-2008 
(83.7% vs. 48.1%). None of the A. baumannii isolates harbored 
the metallo-β-lactamase genes blaIMP-like and blaVIM-like.
To find the molecular basis of the observed high-level 
resistance to aminoglycosides putative 16S rRNA methylase 
genes were assayed. The armA, rmtA, rmtB, rmtC and 
rmtD genes were detected by multiplex PCR using previously 
described primers and conditions.2 All high-level resistant 
strains were armA-positive and carried the blaOXA-23 gene. In 
an attempt to determine the resistance genes location, plasmid 
DNA was isolated using the FlexiPrep Kit (GE Healthcare) and 
separated by electrophoresis in 0.8% agarose gel stained with 
ethidium bromide. All the strains contained only a single 
plasmid of approximately 55 kb. As previously described, PCR 
assays with the plasmid DNA were performed for detection of 
armA and blaOXA-23.
2 The plasmid DNA yielded a specific 315 bp 
PCR product, suggesting the plasmidic location of armA. 
The negative PCR results for blaOXA-23 indicated the probable 
chromosomal location of this gene.
All the OXA-23 carbapenemase and ArmA 16S rRNA 
methylase-producing MDR-Acb strains were analyzed 
by random amplified polymorphic DNA (RAPD) typing as 
previously described.3 A high clonal relatedness (72%) was 
proved between the ArmA-producers (n = 23) and indicated 
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the presence of endemic clone in the AUH during 2010-2011 
(Fig. 1). Three endemic clones were found among the OXA-23 
producers (n = 49) isolated during 2005-2011 (Fig. 2). They were 
presented by 23 strains (77% clonal relatedness), 16 strains 
(61%), and 9 strains (96%), respectively.
To the authors’ knowledge, this is the first report of 
co-production of armA and OXA-23 carbapenemase in 
A. baumannii isolates in East Europe. Recently, North 
American,4 Western European,5 and Asian6,7 studies have 
documented the co-existence of blaOXA-23 and armA, which 
can pose therapeutic challenges. This study illustrates 
the inter-country dissemination of 16S rRNA methylase 
and OXA-23-producing nosocomial A. baumannii isolates. 
Moreover, the results emphasize the need to adopt 
surveillance programs to prevent infection by MDR-Acb in 
this hospital.
Fig. 1 - Dendrogram illustrating the relationship between 23 A. baumannii strains, producing armA 16S rRNA methylase, 
based on analysis with the similarity coefficient (presented as percentage) of RAPD profiles generated with RAPD-4 primer 
(5′-AAGAGCCCGT-3′).
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Fig. 2 – Dendrogram illustrating the relationship between 49 A. baumannii strains, producing OXA-23 carbapenemase, 
based on analysis with the similarity coefficient (presented as percentage) of RAPD profiles generated with RAPD-4 primer 
(5′-AAGAGCCCGT-3′).
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